Editas Medicine Inc (EDIT) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $2.18
• Market Cap: $207.93M
• EPS: $-2.35
• 52-Week High: $4.54
• 52-Week Low: $0.91

Market Sentiment

Editas Medicine Inc currently has a Neutral sentiment score of 0.10.

About Editas Medicine Inc

Editas Medicine, Inc. is a leading clinical-stage genome editing company headquartered in Cambridge, Massachusetts, specializing in cutting-edge genomic therapies for serious genetic disorders. Utilizing its proprietary CRISPR technology, Editas is pioneering transformative treatments that have the potential to fundamentally change the management of various inherited conditions, enhancing patient care and outcomes. With a strong commitment to innovation and a diversified pipeline of therapeut...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Editas Medicine Inc and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does EDIT pay dividends?

Editas Medicine Inc (EDIT) does not currently pay a regular dividend.

What is EDIT's market cap?

Editas Medicine Inc (EDIT) has a market capitalization of $207.93M with a current stock price of $2.18.